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Joint Department of Physics, Division of Radiotherapy and Imaging, The Institute of Cancer Research: Royal Marsden Hospital, Sutton, UK
ABSTRACT
Aim: Thermal isoeffective dose (TID) has not been convincingly validated for application to predict
biological effects from rapid thermal ablation (e.g., using >55 C). This study compares the classical
method of quantifying TID (derived from hyperthermia data) with a temperature-adjusted method
based on the Arrhenius model for predicting cell survival in vitro, after either ‘rapid’ ablative or ‘slow’
hyperthermic exposures.
Methods: MTT assay viability data was obtained from two human colon cancer cell lines, (HCT116,
HT29), subjected to a range of TIDs (120–720 CEM43) using a thermal cycler for hyperthermic
(>2minutes, <50 C) treatments, or a novel pre-heated water bath based technique for ablative expo-
sures (<10 seconds, >55 C). TID was initially estimated using a constant RCEM>43C¼0.5, and subse-
quently using RCEM(T), derived from temperature dependent cell survival (injury rate)
Arrhenius analysis.
Results: ‘Slow’ and ‘rapid’ exposures resulted in cell survival and significant regrowth (both cell lines)
10 days post-treatment for 240 CEM43 (RCEM>43C¼0.5), while 340-550 CEM43 (RCEM>43C ¼0.5) delivered
using ‘rapid’ exposures showed 12±6% viability and ‘slow’ exposures resulted in undetectable viabil-
ity. Arrhenius analysis of experimental data (activation energy DE¼ 5.78±0.04 105 J mole1, fre-
quency factor A¼ 3.27±11 1091 sec1) yielded RCEM¼0.42  e0.0041T which better-predicted cell
survival than using R CEM> 43C¼0.5.
Conclusions: TID calculated using an RCEM(T) informed by Arrhenius kinetic parameters provided a
more consistent, heating strategy independent, predictor of cell viability, improving dosimetry of abla-
tive thermal exposures. Cell viability was only undetectable above 305±10 CEM43 using this
revised measure.
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Introduction
In the treatment of cancer, thermal ablation therapies includ-
ing high intensity focused ultrasound (HIFU), radiofrequency,
microwave and laser ablation have attracted increasing inter-
est over the past few decades. The primary aim of these
therapies has been to heat target tissue rapidly, to achieve
ablative temperatures (>55 C, but often 80 C) in a few
seconds, in order to avoid the cooling effects of blood flow
that make low temperature, long duration (many minutes)
hyperthermia treatment challenging to plan and deliver. The
resultant effect is primary and secondary cell necrosis [1,2].
Despite the minimally and/or noninvasive nature of thermal
ablation treatments, and the advantages these confer, their
use in the clinic has been, at least in part, hampered by lack
of a universally-accepted dosimetric framework [3]. To
address this shortcoming, a parameter known as the thermal
isoeffective dose (TID) commonly used for longer duration,
lower temperature (‘slow’ hyperthermic) thermal exposures
[4–6], was introduced to relate the exposure of tissues to
increased temperatures, held for different lengths of time, to
a given biological endpoint [7]. Equation (1) shows the math-
ematical expression for accumulated thermal dose:
TID ¼
ðs
0
RCEM½  43T tð Þð Þdt (Equation 1)
where TID is the thermal dose in units of cumulative equiva-
lent minutes at 43 C (CEM43), dt is the time at temperature
T (

C), RCEM is approximated as 0.25 for temperatures <43 C
and 0.5 for temperatures >43 C, and s represents the final
time point of the thermal treatment [8]. This formulation of
TID suggests that, for each 1 C increase in temperature
above 43 C, the treatment time should be halved to achieve
the same cytotoxic effect. In practice, the thermal dose must
be quantified over the whole of any hyperthermic tempera-
ture-time treatment profile: including the initial period of
increasing temperature, any period of approximately
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constant temperature, and the cooling period of reducing
temperature.
This relationship has been tested in vitro with a biological
endpoint of cell survival and found to provide a reasonable
prediction of cell death for temperatures between 40 and
47 C, the range for which it was originally formulated
[9–11]. In this temperature range, heat exhibits pleiotropic
effects on the protein and DNA structures of the cells result-
ing in the reduction of their survival [12]. In vivo, a TID value
of 240 CEM43 has been shown to result in coagulative necro-
sis of prostate tissue [13] and uterine fibroids [14] when
magnetic resonance imaging thermometry was used for non-
invasive temperature measurement.
The challenge in thermal biology remains to validate this
‘slow’ hyperthermic concept in vitro for ‘rapid’ ablative treat-
ments. Two issues hinder the ability to achieve this. First,
during ‘rapid’ ablative exposures, temperature inhomogen-
eity within a sample renders the use of an average TID to
represent the dose to all cells inappropriate, since cells may
be subjected to a wide range of different TID. For example,
1 s exposures at 55 C, 56 C and 57 C result in TID of 68,
135 and 270 CEM43 respectively. Thus a difference of þ2 C
can result in a TID difference of 400%. Such differences are
likely to be associated with markedly different cell kill.
Secondly, the time required to achieve temperature transi-
tions during ‘rapid’ ablative exposures becomes significantly
long relative to the total treatment time. Using isosurvival
curves based on data from clonogenic assays, Borelli et al.
demonstrated that ‘slow’ hyperthermic and ‘rapid’ ablative
exposures in vitro in the temperature range of 43.5 C–57 C
held for times ranging from 35min to 1 s, respectively,
resulted in similar survival of Baby Hamster Kidney cells
(BHK) cells when the same thermal dose was delivered [15].
This data, combined with additional studies, led to the sug-
gestion of a cytotoxic isoeffect between the thermal treat-
ment of 135min at 43.5 C (190 CEM43) and 2–3 s at 57 C
(550–820 CEM43) [15,16]. In renal cancer cells, and prostate
cells and tissue TIDs between 800 and 150 000 CEM43 were
necessary to achieve 99% cell kill when temperatures greater
than 55 C were used [17,18]. Also, a TID between 210 and
670 CEM43 was required to kill 99% of prostate AT-1 cells
using temperatures between 40 and 60 C. In experiments
undertaken in skin tissue has been shown that TID >10 000
CEM43 is needed to kill all cells [19]. Experiments in human
and pig skin in vivo have shown that at temperatures >55 C
the Arrhenius plots are not linear, making it difficult to calcu-
late the activation energy suggesting the existence of add-
itional transition points for the RCEM value in addition to
those established at 43 C [20,21]. For example, in-vitro stud-
ies with hepatocellular cancer cells have shown that in the
temperature range of 50–60 C RCEM can be as high as 0.72
[22], and in prostate cells and tissue can vary from 0.47 to
0.83 [18].
This study aims to assess whether the method for calcu-
lating TID derived from long duration hyperthermia experi-
ments is suitable for quantifying dose for ablative
techniques. The cytotoxic effects of ‘slow’ hyperthermic and
‘rapid’ ablative thermal exposures are compared using
in-vitro models of colon adenocarcinoma at times up to
14 days after thermal insult. We define ‘slow’ hyperthermic
exposures as those lasting more than 2min at temperatures
in the range of 44–50 C, in which there is temperature
homogeneity throughout the sample and the thermal insult
can, therefore, be described by a spatially-averaged TID. We
define ‘rapid’ ablative exposures as being short duration with
clinically ablative intention, (i.e., <10 s, in the temperature
range 55–64 C) during which temperature homogeneity can-
not be achieved, and for which spatially-averaged TID does
not provide a meaningful representation of the exposure.
Instead, the local TID at a fixed location where the dose is
designed to be minimal is denoted as minTID. In order to
achieve ‘rapid’ ablative exposure conditions, a heating bath
method which incorporates temperature measurement at
100Hz at multiple positions in a (500ll) polymerase chain
reaction (PCR) tube was developed. The cytotoxic effects of
‘rapid’ ablative heating to temperatures above 55 C were
compared with heating using a cell thermal cycler (PCR
machine) suitable for ‘slow’ hyperthermic exposures in the
range of 44–50 C. The TID required to reduce cell viability in
vitro to undetectable levels of 10 days (chosen as the best
indicator of the therapeutic effect, see discussion) after
exposure was investigated for both ‘rapid’ ablative and ‘slow’
hyperthermic thermal exposures, and a significant difference
was demonstrated between the 2 delivery regimes.
Materials and methods
Cell culture
HCT116 and HT29 cells (provided Dr. Yuen-Li Chung, The
Institute of Cancer Research, London) were maintained in a
sub-confluent monolayer at 37 C in 75cm2 flasks in a
humidified atmosphere containing 5% CO2. They were
propagated using Hyclone McCoys 5 A medium supple-
mented with 10% hybridoma cell culture grade fetal bovine
serum ((FBS) USA (cat. no. F2442, SIGMA, Poole UK)), 2mM L-
glutamine, 50U/ml penicillin, 50mg/ml streptomycin B,
0.25 lg/ml amphotericin B and sub-cultured using Accutase
(SIGMA). Screening for mycoplasma contamination was car-
ried out on a monthly basis.
Thermal exposures and thermometry
For all thermometry measurements, thermocouples were
connected to a DELL laptop (IntelVR CoreTM i5-2540M CPU at
2.6GHz, RAM 8GB) (Round Rock, Texas) via a cDAQ-9171
National Instruments data logger (Austin, Texas) (Figure 1).
For experiments involving ‘slow’ hyperthermic exposures
(lasting between 112 s and 1 h, and with peak temperatures
between 50 (high) and 44 C (low), with control cells being
maintained at 37 C), a Biorad Tetrad2 DNA Engine polymer-
ase chain reaction (PCR) thermal cycler (Hercules, CA, USA)
was used, the specifications of which are shown in Table 1.
The thermal cycler delivered preprogramed temperatures for
specified lengths of time as shown in Table 2. In order to
determine the TID for a variety of exposure conditions,
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T-type thermocouples with 0.2mm wire diameter, 0.57mm
probe diameter and accuracy of ± 0.5 C up to 125 C (cat.
no. 6212164, RS Instruments, Corby, UK) were used to deter-
mine the temperature at a number of positions within the
fluid contained in the PCR tube as described previously [23].
Temperature homogeneity within the treatment volume was
within 0.3 C [23]. The T-type thermocouple offset was esti-
mated as 0.325 C± 0.025 C by the National Physical
Laboratory (Teddington, UK) using a source of constant tem-
perature at 20 C. Temperature measurements used to calcu-
late TIDs were corrected for this offset error.
Measurements were made simultaneously in 5 PCR tubes
(0.2ml medical grade, wall thickness 0.375 ± 0.025mm
Corning Inc., NY) containing the same volume of medium
(60ll) as used for the cell studies, but with no cells present.
One thermocouple was placed in each tube with the inten-
tion of sampling temperature in a number of positions, in
order to assess the variation in thermal dose. Temperature,
recorded at 100Hz simultaneously for all 5 sensors using cus-
tom-written Matlab software, was converted to TID using
Equation (1). These experiments were repeated 5 times in
order to measure the maximum range of actual thermal
dose for all the time/temperature combinations used for
‘slow’ hyperthermic exposures. Since a variety of thermo-
couple measurement positions were sampled, these data
were averaged in order to quantify the ‘spatially-averaged’
TID for each ‘slow’ exposure condition, in order to attempt
to represent the dose delivered when homogeneous tem-
perature distributions were achieved.
For cell survival experiments, cells from stock culture were
trypsinized, and 60ll of the resulting solution, at 4 C and a
density of 2 106 cells/ml, transferred to the PCR tubes. The
cell containing solutions were heated using the PCR thermal
cycler, and the 3 target-temperature step cycles were pro-
gramed to give TIDs of 0 CEM43 using exposures of 37 C for
15min (control), 120 CEM43 using exposures of 44 C for
60min, 46 C for 15min, and/or 48 C for 3min and 45 s, 240
CEM43 using exposures of 46 C for 30min, 47 C for 15min,
48 C for 7min and 30 s, and/or 50 C for 112.5 s, 340 CEM43
using exposures of 48 C for 10min and 36 s, 480 CEM43
using exposures of 48 C for 15min, 680 CEM43 using expo-
sures of 49 C for 10min and 36 s and 720 CEM43 using expo-
sures of 49 C for 11min and 15 s (Table 2). Before and after
thermal exposure, cells were cooled to 4 C for 1min to nor-
malize their intracellular processes. At the end of the treat-
ment, 25 ll aliquots of control and treated cells were
transferred to 24- and 96-well plates to allow fluorescent
microscopy and MTT cell viability assays to be performed,
respectively.
For ‘rapid’ ablative thermal exposures, cells in 220 ll
medium in 0.5ml PCR tubes were treated with a TID of 205,
410 or 820 CEM43 using 3 s exposures to temperatures of
55 C, 56 C and 57 C respectively. In order to evaluate the
efficacy of the technique for delivering quantifiable thermal
dose to a population of cells, 5 fast response PFA-insulated
0.078mm k-type thermocouples (5SRTC-TT-KI-40-1M, Omega,
Stamford, Connecticut) were placed at various positions
within PCR tubes containing 180 ll of medium, as shown in
Figure 2(A), and the wires tethered using tape.
Thermocouple (tc) 1 was always placed as close to the bot-
tom of the tube as possible, with tc2 adjacent to it, and tc 5
just below the surface of the solution. The other sensors
were positioned roughly as shown but the positions were
not designed to be reproducible since the aim was only to
sample temperature and thermal dose away from the bot-
tom of the tube and the top of the solution to verify that
these positions represented a minimum and (approximately)
maximum thermal dose, respectively.
Before exposure, cells were kept on ice (4 C) at a concen-
tration of 2 106 cells/ml. A water bath preheated to 65 C
was used in an attempt to minimize the discrepancy
between the intended and actual (i.e., that calculated from
measured temperature and exposure duration) TID. Medium
(180 ll) without cells was pre-warmed in this water bath,
with the PCR tube held such that the surface of the medium
was below that of the heated water, in order to minimize
the rate of cooling during the heating phase.
Temperature 
Data logger 
Laptop 
Thermal 
cycler 
Heang 
block 
Thermocouples
Thermocouple connectors
PCR tubes 
Figure 1. ‘Slow’ hyperthermic thermal exposure of cells achieved using a PCR
thermal cycler. 60lL of cells in a medium in plastic walled PCR tubes were
placed in individual wells with the heating block. Thermocouples connected to
a data logger were used to record temperature with one thermocouple per
tube. The thermal dose was delivered using the range of heating cycles
detailed in Table 2.
Table 1. Biorad Tetrad2 DNA Engine PCR thermal cycler specifications.
Thermal cycler specifications
Thermal accuracy ±0.3 C at 90 C
Thermal uniformity ±0.4 C well-to-well at 90 C
Ramping speed up to 3 C / sec
Power: 850 W max
Minimum thermal increment size 0.1 C
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When the temperatures recorded by all the indwelling
thermocouples exceeded 63 C, 40 ll of medium containing
cells were rapidly pipetted into the bottom of the PCR tube
(in order to contribute to providing a minimum thermal dose
at the bottom of the tube, as demonstrated in experiments
in which red ink replaced cells (Appendix A and video A and
B)). The pipette tip was inserted into the heated fluid and
the cool medium injected soon enough so that heating prior
to injection was ignored. The aim was to achieve a tempera-
ture rise as rapid as possible by exploiting the mixing of a
Table 2. Details of ‘slow’ hyperthermic thermal exposures averaged over 5 experiments achieved using the PCR thermal cycler as the heating source.
Intended TID (CEM43) Step 2 – Heating (target temperature / Duration) Actual TID (CEM43) Max. discrepancy (actual / target) (%)
0 (control) 37oC / 15min 0 N/A
120 44oC / 60min 123 ± 10 10.8
46oC / 15min 127 ± 7 11.6
48oC / 3 min45 sec 125 ± 8 10.8
240 46oC / 30min 248 ± 12 8.3
47oC / 15min 248 ± 12 8.3
48oC / 7.5min 247 ± 10 7
50oC / 112.5 sec 237 ± 13 4
340 48oC / 10.6min 346 ± 20 7.6
480 48oC / 15min 500 ± 21 8.5
680 49oC / 10.6min 698 ± 40 8.5
720 49oC / 11min15 sec 740 ± 56 10.5
Only step 2, the steady-state heating cycle is shown. Steps 1 and 3 involve the tubes being kept at 4 C for 1min before and after each thermal exposure.
Results are presented as mean ± std dev of 5 independent experiments.
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Figure 2. ‘Rapid’ ablative thermal dose delivery. (A) indicates how 5 K-type thermocouples were positioned in the pre-heated medium. Also shown is roughly
where the cells were pipetted into the pre-heated solution for an intended exposure of 57 C for 3 s. (B and C) show typical examples of the temperature histories
measured for such an exposure which was intended to provide a minimum TID of 820 CEM43. The resultant exposures are summarized in terms of thermal dose
and peak temperature in Table 3.
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small volume of cool liquid containing cells with a much
larger heated volume, thus ideally resulting in an unaltered
equilibrium (hot) temperature. As soon as tc 1 reached
56–57 C the tube was taken out of the water bath and the
bottom of it placed into dry ice within 1–2 s. This tech-
nique was chosen to minimize the duration of the cooling
phase for ‘rapid’ ablative exposures.
For data processing purposes, the ‘increasing temperature’
phase of ‘rapid’ ablative exposures begins after the injection
of cells into the PCR tube (as soon as the temperature
recorded by tc 1 reaches a minimum) and lasts until the
temperature recorded by the bottom thermocouple (i.e., that
placed deepest into the PCR tube) reaches within 0.6 C
(twice the measurement uncertainty) of the peak tempera-
ture (defined as the steady-state temperature plus the meas-
urement uncertainty of 0.3 C). Cooling phase duration is
calculated similarly as the time between the temperature of
the bottom thermocouple falling 0.6 C below peak tempera-
ture to reaching 39 C. Once the temperature of the lowest
placed thermocouple dropped below 10 C the cells were re-
suspended twice and plated in 96-well plates by pipetting
25ll of the experimental cell mixture into 80 ll of unex-
posed media. The steady-state phase was defined as the
period between the end of the increasing temperature phase
and the cooling phase. Control cells were exposed for 10 s at
room temperature in the same way as thermally-
exposed cells.
Cell viability: MTT
An MTT assay, based on the reduction of the tetrazolium dye
MTT 3–(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide to formazan in mitochondria, was used to deter-
mine cell viability. The optical density (OD) signal from the
assay correlates linearly with live cell number over a range of
0–105 cells. 20 ll MTT dye (5mg/ml)/100 ll of medium was
added to the cells in 96 well plates, which were then incu-
bated at 37 C for 2 h. 100 ll of 10% sodium dodecyl sulfate
(SDS) was then added to each well. After overnight incuba-
tion at 37 C, the signal intensity at 550 nm was measured
using a microplate reader. The average OD of wells contain-
ing medium only (n¼ 4) was subtracted from each signal in
order to provide a background correction, the resulting aver-
age signal from control cells was then normalized to 100%
and the individual signal from treated cells was expressed as
a percentage of the control:
Cell viability %ð Þ ¼ ODtreated=Average ODcontrolð Þ  100
(Equation 2)
The viability of both cell lines was assessed up to 14 days
after ‘slow’ hyperthermic exposures of 0, 120, 240, 480 and
720 CEM43 (3 independent experiments, n¼ 4 per dose)
(Figures 3 and 4). The objective of these experiments was to
characterize the long-term survival of the cells at regu-
lar intervals.
Cell viability after ‘slow’ hyperthermic exposures was
assessed one day (n¼ 4 samples per condition) after treat-
ment (Figure 5) so that the cytotoxic effects of both necrosis
and programed cell death [23] could be observed at a time
when the proliferation of survivors should be minimal.
In order to compare the viability of cells after ‘rapid’
ablative (n¼ 2) and ‘slow’ hyperthermic (n¼ 2) exposures
(Figure 6), day 10 after treatment was chosen to give
adequate time for survivors to attach to the substrate,
exhibit clonogenic potential and proliferate enough for a
signal to be detected with the MTT assay. Viabilities lower
than 3% relative to the controls were defined as
undetectable.
Cell visualization: fluorescent microscopy
Confocal fluorescent microscopy was used to visualize ther-
mally treated cells in order to investigate morphological
changes induced by heating and to assess the level of cellu-
lar adhesion to the substrate and any subsequent prolifer-
ation as a function of time. Following treatment, cells were
placed on poly-L-lysine coated coverslips in 500 ll of
medium and were allowed to attach. At various time points
(immediately, and 2, 4, 7 and 14 days after treatment), plated
coverslips were submerged in 4% paraformaldehyde for
20min to fix cells. They were then washed three times with
PBS containing calcium and magnesium, and permeabilized
for 10min with 0.1% Triton X-100. Cells were washed three
times with PBS, and nonspecific binding sites were blocked
with PBS buffer containing 5% semi-skimmed milk. Actin
Figure 3. Average viability of HCT116 and HT29 colon cancer cells assessed up
to 14 days after ‘slow’ hyperthermic exposures with TIDs of 0, 120, 240, 480 and
720 CEM43 achieved using 37 C, 46 C, 47 C, 48 C for 15min and 49 C for
11min and 15 s, respectively. Results are presented as means ± SEM for three
independent experiments per data point.
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microfilaments were then stained with TRITC-conjugated
phalloidin in blocking buffer (1:500 dilution) for 1 h at room
temperature. Coverslips were washed five times with PBS,
mounted on slides using anti-fade gold (molecular probes)
and visualized using a 20 lens (EC Plan-NeoFluar 20x, NA
0.5) on a Carl Zeiss confocal fluorescent microscope (Zeiss
LSM700, Germany).
The relationship between TID and Arrhenius coefficients
The activation energy (DE) and frequency factor (A) of the
‘slow’ hyperthermic and ‘rapid’ ablative reactions were calcu-
lated using a method described in [18]. Briefly assuming a
‘top-hat’ thermal history for both ‘slow’ hyperthermic and
‘rapid’ ablative thermal exposures, the cell injury rate (k) was
calculated using:
S ¼ ek  t (Equation 3)
where S is the experimentally determined fractional cell sur-
vival, k is the cell injury rate (sec1) and t is the treatment
time of cells (sec) at a constant temperature. An Arrhenius
plot of Ln (k) versus the inverse of the absolute temperature
1/T (103 K1) was then drawn. The activation energy (DE) is
a function of the slope of the straight line fit of the data in
the Arrhenius plot and the frequency factor can be calcu-
lated from its y-intercept using Equation (5):
k ¼ A eDE= Rg  Tð Þ (Equation 4)
Ln kð Þ ¼ Ln Að Þ –DE= Rg  Tð Þ (Equation 5)
where k is the cell injury rate (sec1), A is the frequency fac-
tor (sec1), DE is the activation energy (J mole1), Rg is the
universal gas constant (8.314 J mole1 K1), and T is the
absolute temperature (K). To convert between the Arrhenius
and the TID model, RCEM was calculated:
RCEM Tð Þ ¼ eDE= Rg  T  Tþ1ð Þ½  (Equation 6)
where RCEM(T) is the RCEM value at temperature T, T is the
absolute temperature (K) [8]. Inserting RCEM(T) into Equation
(1) allows calculation of a temperature-dependent TID for
comparison with the standard method of calculation.
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Figure 4. Microscopic visualization of actin microfilament staining of HCT116 cells (A, B and C) and HT29 cells (D, E and F) after ‘slow’ hyperthermic exposures with
TIDs of 0 (columns A and D), 120 (columns B and E) and 240 (columns C and F) CEM43 assessed up to 14 days after treatment. Results are presented as representa-
tive fluorescent microscopy images of fixed cells stained with phalloidin-TRITC obtained using confocal microscopy at 200 times magnification.
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Statistical analysis
For the ‘slow’ hyperthermic exposure thermal dose quanti-
fication, the 5 repeat datasets were averaged. The results
were then averaged for 5 repeats of each exposure to
obtain a mean and standard deviation. Where cell viability
data for three independent experiments were obtained,
results are presented as mean ± SEM. Where 4 replicates of
a single experiment are presented they are analyzed as
mean ± standard deviation (std. dev.), as are all thermal
data. All experiments were performed at least 3 times.
Results
Thermometry
The actual thermal dose delivery for ‘slow’ hyperthermic
(PCR) exposures (5 repeats with 5 PCR tubes in 5 block posi-
tions using 1 thermocouple per PCR tube) for intended doses
of 0, 120, 240, 340, 480, 680 and 720 CEM43 is shown in
Table 2. The dose delivered is within 12% of that intended.
This demonstrates the good reproducibility of the actual
thermal dose delivery.
Figure 2(B,C) shows examples of the temperature his-
tory profiles measured using 5 thermocouples during
a ‘rapid’ ablative thermal exposure intended to expose
the cells to a thermal dose of 820 CEM43 using a 3 s
exposure at an intended peak temperature of 57 C.
Table 3 shows the total treatment time, maximum
recorded temperatures and the total accumulated TID for
each thermocouple (TC) location, during ‘rapid’ ablative
thermal exposures. These measurements show a wide
variation in measured TID throughout the samples. For
example, for an intended treatment of 57 C for 3 s
giving a TID of 820 CEM43 the actual measured levels
were 540 (tc1), 610 (tc 2), 720 (tc 3), 970 (tc 4) and 1450
CEM43 (tc 5). Table 4 shows the heating up, steady state
and cooling downtime, and the associated TID as deter-
mined by the thermocouple located in the bottom of
the tube.
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Figure 4. Continued.
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Viability of cells subjected to ‘slow’ hyperthermic
heating regimes
The viability (normalized to the value for controls) of
HCT116 and HT29 colon cancer cells exposed to 0, 120, 240,
480 and 720 CEM43, achieved using ‘slow’ hyperthermic
exposures, was determined immediately, 1, 2, 4, 7 and
14 days, after treatment in 3 replicated experiments for each
dose in order to characterize the longitudinal response of
cells to a range of TIDs and to determine when to assess
viability and whether survivors retain their proliferative char-
acteristics. MTT assays showed that within 7 days of treat-
ment, exposure of both cell lines to 480 CEM43 resulted in
undetectable viability (Figure 3). A TID of 120 CEM43
resulted in a reduction in the viability of HCT116 cells to
40% and HT29 cells to 22% one day after treatment,
with the remaining cells retaining their clonogenic potential
and proliferating. 95 ± 2% of HCT116 and HT29 cells treated
with a TID of 240 CEM43 were non-viable at 4 and 7 days
after treatment, respectively. However, the remaining cells
in these two populations also retained their proliferative
potential and 14 days after treatment the measured viability
of HCT116 cells was 48 ± 21% that of control cells, and for
similarly treated HT29 cells was 44 ± 14% (Figure 3).
Confocal fluorescent microscopy showed that controls of
both cell lines, attached to the well plates 2 days after sham
treatment. These had attached and spread on the substrate,
exhibiting bright microfilament staining and increasing
numbers as shown in Figure 4(A1–A4,D1–D4). Cells from
both lines treated with a TID of 120 CEM43, had an abnor-
mally rounded appearance 2 days after treatment (Figure
4(B2,E2)) but had attached to the substrate by day 4 (Figure
4(B3,E3)). Cell division was evident 7 and 14 days after treat-
ment (Figure 4(B4,B5,E4,E5)). A population of live, rounded,
loosely attached or floating cells was also seen 2 days after
treatment following a TID of 240 CEM43 (Figure 4(C2,F2)).
After 4 days 2 distinct populations were evident. One
showed bright actin filament staining and the second was
more faintly stained (Figure 4(C3,F3)). In addition, some of
the loosely attached and/or floating HCT116 and HT29 cells
fully attached to the substrate and proliferated to form col-
onies (Figure 4(C4,C5,F4,F5)).
Dependence of cell viability on temperature and
exposure duration
The validity of TID for ‘slow’ hyperthermic treatments deliv-
ered to both cell lines using a variety of temperature/dur-
ation conditions to achieve the same intended thermal
doses was investigated for TIDs of 120 and 240 CEM43 one
day after treatment. This time point accounts for cells that
have died both from instantaneous necrosis and by pro-
gramed cell death signaling pathways and excludes viability
from the proliferation of unaffected survivors, as shown in
Figure 5. For the lowest dose, a TID of 123 ± 11 CEM43 was
delivered using 44 C for 60min, 46 C for 15min and 48 C
for 3min and 45 s. These doses resulted in viabilities (rela-
tive to controls) one day after treatment for HCT116 cells ofTa
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40± 3%, 36 ± 1% and 41± 2%, respectively and for HT29 cells
of 42 ± 2%, 41± 1% and 50± 5% respectively. A TID of
242± 18 CEM43 was delivered using 46 C for 30min, 48 C
for 7.5min and 50 C for 112.5 s. This dose resulted in viabil-
ities 1 day after treatment of 34 ± 4%, 38 ± 1% and 38± 2%
respectively (HCT116) and from 21 to 23 ± 2% (HT29) relative
to controls (Figure 5(B)). These results show that within each
thermal dose group and measurement uncertainties the
results do not vary, for a given peak temperature/exposure
duration combination.
Figure 6 shows a comparison of the effects of ‘slow’
hyperthermic and ‘rapid’ ablative, thermal delivery on cell
viability 10 days after treatment (as an indicator of maximum
therapeutic response) for intended thermal doses between
240 and 680 CEM43. This time point was chosen in order to
provide enough time for the small number of cells that were
not killed to recover from the effects of heat and to prolifer-
ate sufficiently to give a detectable signal on the MTT assay.
Cells treated with a TID of 248± 12 CEM43 delivered by heat-
ing to 47 C for 15min had viabilities of 11 ± 2% (HCT116)
and 40 ± 10% (HT29) relative to sham-exposed cells.
Treatment of both cell lines with TID of 345± 20, 500 ± 21,
700 ± 40 CEM43, using exposures longer than 10min, resulted
in undetectable cell viability after 10 days. Using ‘rapid’ abla-
tive thermal exposures shorter than 10 s duration, with a tar-
get temperature of up to 57 C, resulted in HCT116 cells
having minimum TID (defined as that measured at tc1) val-
ues, shown in Table 3, of 240 (tube 1), 270 (tube 2), 370
(tube 3), 440 (tube 4), 510 (tube 5), 560 (tube 6) and 680
(tube 7) CEM43. These resulted in viabilities relative to control
0
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Figure 5. Comparison of cell viability for different ‘slow’ hyperthermic thermal exposure regimes. HCT116 and HT29 cell viability treated with a TID of 120 CEM43
(A) and 240 CEM43 (B) and assessed 1 day after treatment using the combinations of time and temperature shown in each graph. Results are presented as
means ± std. dev. (n¼ 4) of an experiment that has been repeated three times with similar results. The data show that cell viability was independent of the delivery
strategy over the range tested.
Table 4. ‘Rapid’ ablative thermal exposures: the duration of, minimum TID accumulated in, and percentage of the total minTID in, each phase (increasing tem-
perature, steady-state temperature, and reducing temperature) of the treatment as recorded by the lowest placed thermocouple (tc 1) for each test.
Rising temp.
phase
duration (s)
Rising temp.
phase
TID (CEM43)
% Dose
Rising temp.
Steady state
phase
duration (s)
Steady state
TID (CEM43)
% Dose
steady temp
Cooling
phase
duration (s)
Cooling
phase
TID (CEM43)
%
Dose cooling
Total
TID (CEM43)
HCT116 Tube 1 4.3 53 22% 1.4 147 61% 2.7 40 17% 240
Tube 2 4.2 65 24% 1.3 165 61% 2.8 40 15% 270
Tube 3 2 105 28% 1.2 215 58% 2.8 51 14% 371
Tube 4 1.4 95 22% 0.9 182 42% 3.8 158 36% 435
Tube 5 4.5 130 25% 1.5 300 59% 3.2 80 16% 510
Tube 6 2.2 150 27% 1.2 360 64% 1.6 50 9% 560
Tube 7 4 160 24% 2.1 417 61% 3.9 103 15% 680
HT29 Tube 1 1.9 59 22% 2 196 73% 1.5 15 6% 270
Tube 2 1.9 115 34% 1.5 200 59% 1.4 25 7% 340
Tube 3 3.5 61 13% 1.9 353 76% 3.5 52 11% 466
Tube 4 6.76 211 43% 0.84 239 48% 2.2 43 9% 493
Tube 5 1.27 120 22% 1.13 360 67% 2.3 60 11% 540
Tube 6 2.6 115 18% 2.1 370 59% 3.8 140 22% 625
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cells 10 days after treatment of 94 ± 2, 67 ± 1, 23 ± 1, 8 ± 4,
9 ± 4, 5 ± 1 and <2 ± 2%, respectively (Figure 6(A)). HT29 cells
with minimum delivered TID (Table 3) of 270 (tube 1), 340
(tube 2), 470 (tube 3), 490 (tube 4), 540 (tube 5) and 630
(tube 6) CEM43 exhibited viabilities 10 days after treatment of
79± 5, 17 ± 1, 15 ± 10, 13 ± 4, 8 ± 3 and <1± 1%, respectively,
(Figure 6(B)). These results show that compared to
similar thermal doses, ‘slow’ hyperthermic thermal exposures
result in greater cytotoxicity than that achieved with
‘rapid’ heating.
Dependence of RCEM on temperature
The cell injury rates caused by the exposure of cells to the
‘slow’ hyperthermic (Figure 5) and ‘rapid’ ablative (Figure 6)
treatments were calculated using Equation (3). HCT116 tubes
1 and 2 and HT29 tube 1 (Table 3) were excluded from these
calculations because a significant percentage of the cells in
these tubes were unaffected by the thermal insult and had
proliferated by the time of the assessment, 10 days after
treatment. HCT116 tube 7 and HT29 tube 6 (Table 3) were
also excluded from these calculations because in these tubes
survival was undetectable making the calculation of injury
rates using Equation (3) impossible. Table 5 shows that
‘rapid’ ablative thermal reactions at 56–57 C caused injury
rates of 0.7 to 1.5 s1 compared to ‘slow’ hyperthermic treat-
ments in the temperature range of 44–50 C where these
ranged from 2.4 104 (44 C) to 1.3 102 s1 (50 C).
Figure 7(A) shows an Arrhenius plot of the logarithm of the
experimentally-derived injury rates versus the inverse of the
absolute temperature. The error bars depict the injury
rate uncertainty due to the variation in the experimentally
measured cell survival. A straight line fit of the data is
possible in the temperature range of 44–57 C. Using
Equation (5) the activation energy (DE) and frequency
factor (A) of the thermal insults to the HCT116 and HT29
cells were calculated to be DE¼ 5.78 ± 0.04 105 J mole1
and A¼ 3.27 ± 11 1091 s1. The variation in DE and A has
been calculated from Arrhenius plots utilizing the minimum
(mean minus standard deviation) and maximum (mean plus
standard deviation) experimentally-derived injury rates for
each data point. The cell survival S as predicted from the
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Figure 6. Comparison of cell viability following ‘rapid’ ablative and ‘slow’ hyperthermic thermal exposures. Ten days after treatment, the viability of HCT116 (A)
and HT29 (B) cells treated with ‘rapid’ ablative exposures (quantified as minTID) was greater than that for cells treated with ‘slow’ hyperthermic thermal exposures
(quantified as average TID). Results are presented as means ± std. dev. of two datasets from a single experiment that has been repeated 3 times with simi-
lar results.
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Arrhenius coefficients for each cell line was re-calculated
using Equations 3 and 4, and were compared to the experi-
mental cell survival data obtained for the HCT116 and HT29
cell lines. Table 5 and Figure 7(B) show that the Arrhenius
analysis provides a reasonable prediction of the survival of
the 2 cell lines in the temperature range used. Of a total of
20 tests, 14 tests gave predicted and actual cell survival
which agreed within 5%, 2 agreed within 10% and 4
within 16%.
The activation energy DE was used to calculate RCEM (T)
using Equation (6) at the temperatures for which viability
was assessed (Table 5 and x-axis points of Figure 7(A)). RCEM
was calculated to be equal to 0.502 ± 0.002 at 44 C, and
increased with temperature, rising to 0.530 ± 0.002 at 57 C.
The error in RCEM (T) for each data point was calculated using
the minimum and maximum DE. Figure 8 shows a plot of
RCEM(T) versus temperature with an exponential fit in the
temperature range 44–57 C described by:
RCEM Tð Þ ¼ 0:42  e0:0041  T (Equation 7)
where T is the temperature (

C). In Figure 9, the cell viability
results from Figure 6 (for both ‘slow’ hyperthermic and ‘rapid’
ablative TIDs) re-plotted using RCEM (T), show that viability
became undetectable at a temperature-corrected TID of
305±10 CEM43 for both HCT116 and HT29 cells, irrespective
of the heating strategy. These results show that Arrhenius ana-
lysis can predict the survival of cells with reasonable accuracy
and can provide the basis for a more accurate interpretation
of the TID equations if a temperature-dependent RCEM is used.
Discussion
TID has been used as a parameter to describe the effects of
heat in a variety of biological models [23–25]. The TID model
Table 5. Calculation of cell injury rate and comparison of cell survival predicted by the Arrhenius model with that measured experimentally: the temperature
and duration (assuming top-hat thermal histories) of ‘slow’ hyperthermic and ‘rapid’ ablative exposures have been used to calculate the cell injury rate.
Experimental identifier /
TID (CEM43)
Heating (steady state
temperature / exposure
duration assuming top hat
thermal history)
Calculated injury rate k
(sec-1)
Calculated survival from
the kinetic parameter of
the Arrhenius model (DE
and A)
Experimental fractional
survival (mean ± std. dev)
Percentage difference
between predicted and
actual survival
(mean ± std. dev) (%)
HCT116 / 120 44oC / 3,600 sec 2.5 ± 0.2 104 0.46 ± 0.02 0.40 ± 0.03 6 ± 5
HCT116 / 120 46oC / 900 sec 1.14 ± 0.03 103 0.46 ± 0.02 0.36 ± 0.01 10 ± 3
HCT116 / 120 48oC / 225 sec 4.0 ± 0.3 103 0.52 ± 0.02 0.41 ± 0.02 11 ± 4
HCT116 / 240 46oC / 1800 sec 6.0 ± 0.6 104 0.21 ± 0.02 0.34 ± 0.04 13 ± 6
HCT116 / 240 48oC / 450 sec 2.15 ± 0.06 103 0.22 ± 0.02 0.38 ± 0.01 16 ± 3
HCT116 / 240 50oC / 112.5 sec 8.6 ± 0.4 103 0.24 ± 0.03 0.38 ± 0.02 14 ± 5
HT29 / 120 44oC / 3,600 sec 2.4 ± 0.1 104 0.46 ± 0.02 0.42 ± 0.02 4 ± 4
HT29 / 120 46oC / 900 sec 9.9 ± 0.3 104 0.46 ± 0.02 0.41 ± 0.01 5 ± 3
HT29 / 120 48oC / 225 sec 3.1 ± 0.5 103 0.52 ± 0.02 0.5 ± 0.05 2 ± 7
HT29 / 240 46oC / 1800 sec 8.2 ± 0.5 104 0.21 ± 0.02 0.23 ± 0.02 2 ± 4
HT29 / 240 48oC / 450 sec 3.5 ± 0.2 103 0.22 ± 0.02 0.21 ± 0.02 1 ± 4
HT29 / 240 50oC / 112.5 sec 1.31 ± 0.08 102 0.24 ± 0.03 0.23 ± 0.02 1 ± 5
HCT116 Tube 3 / 370 56.5oC / 2 sec 0.75 ± 0.02 0.18 ± 0.03 0.23 ± 0.01 5 ± 4
HCT116 Tube 4 / 440 56.5oC / 2.3 sec 1.1 ± 0.2 0.13 ± 0.03 0.08 ± 0.04 5 ± 7
HCT116 Tube 5 / 510 56.5oC / 2.6 sec 0.9 ± 0.2 0.10 ± 0.02 0.09 ± 0.04 1 ± 6
HCT116 Tube 6 / 560 57oC / 2 sec 1.5 ± 0.1 0.09 ± 0.02 0.05 ± 0.01 4 ± 3
HT29 Tube 2 / 340 56oC / 2.5 sec 0.69 ± 0.02 0.2 ± 0.03 0.18 ± 0.01 2 ± 4
HT29 Tube 3 / 470 56.5oC / 2.4 sec 0.79 ± 0.03 0.12 ± 0.03 0.15 ± 0.01 3 ± 4
HT29 Tube 4 / 490 57oC / 1.8 sec 1.1 ± 0.2 0.11 ± 0.03 0.13 ± 0.04 2 ± 7
HT29 Tube 5 / 540 57oC / 2 sec 1.3 ± 0.2 0.09 ± 0.02 0.08 ± 0.03 1 ± 5
The activation energy DE and frequency factor A calculated from the Arrhenius plot shown in Figure 7(A) have been used to calculate the Arrhenius predicted
cell survival using Equations 3 and 4 and compare it with the experimental cell survival. The mean difference and standard deviation between the experimental
and predicted cell survival expressed as a percentage are shown in the last column.
(A)
(B)
Figure 7. Arrhenius plot of both ‘slow’ hyperthermic and ‘rapid’ ablative expo-
sures for HCT116 and HT29 cells (A). The cell injury rate was calculated for both
‘slow’ hyperthermic exposures shown in figure 5 and the ‘rapid’ ablative treat-
ments in figure 6. A comparison of the experimentally detected cell survival to
that calculated using the Arrhenius kinetic parameters DE and A, and Equations
3 and 4 (B) is shown.
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does not directly predict the survival of cells after thermal
exposure and different TID thresholds for cell and tissue
damage have been postulated. These TID thresholds depend
on the tissue under investigation (e.g., skin, cornea, tumor,
nerves, etc.), the degree of damage (minor, extensive or
total) and the method of its assessment (e.g., chronic vs.
acute, clonogenic potential vs. membrane disruption vs.
metabolic assays vs. histology). Detailed reviews of TID
thresholds for a variety of biological damage endpoints can
be found elsewhere [24,25] and show the extensive variation
of the sensitivity of cells and tissues to thermal insults [26].
However, TID’s simplicity and the ease with which TID can
normalize the biological effects of different thermal histories
has helped its adoption in the clinic where a TID of 240
CEM43 is widely accepted as the minimum required for abla-
tive thermal treatments [27]. However, this value derives
from in-vitro studies using exposure times that are signifi-
cantly longer, and peak temperature rises that are signifi-
cantly lower, that are commonly used for tissue ablation. For
this reason, the relationship between TID and the biological
consequences of the rate of heat delivery has been investi-
gated in HCT116 and HT29 cell lines in this study. These cells
represent well-characterized in-vitro models of colon cancer
adenocarcinoma with epithelial morphology and doubling
times of 24 h [28,29]. Unless stated otherwise, TID is calcu-
lated using Equation (1) with R¼ 0.5 for T> 43 C and
R¼ 0.25 for T< 43 C.
The PCR thermal cycler used to deliver intended pre-
determined thermal dose during ‘slow’ hyperthermic heating
gave the required TID to within better than 12% in all cases
studied (Table 2). Figure 3 shows the timeline over which
cells respond to thermal insult before ultimately either recov-
ering or succumbing to death. The viability of both cell lines
treated with a TID of 240 CEM43 delivered using ‘slow’ hyper-
thermic exposures decreases for 2 days after treatment.
These cells were abnormally rounded and tended to aggre-
gate in a manner different from that for healthy adherent
cells, as shown by confocal microscopy (Figure 4(C2,F2)).
Figure 3 also shows that the rate of cytotoxicity slows
between day 2 and day 4, when microscopy shows clear evi-
dence of cell attachment, and reduced rounding and aggre-
gation (Figure 4(C3,F3)). In addition, 2 distinct cell
populations are seen in both images. One retains its clono-
genic potential (as demonstrated by an increase in the num-
ber of cells on day 7 and day 14) and shows bright actin
filament staining (and increasing size), and the second exhib-
its fainter actin staining. We hypothesize that this second
population of cells are dying (arrowed areas, Figure 4(C3,F3).
By day 7, cells treated with a TID of 240 CEM43 had a viabil-
ity of <5% (Figure 3). Although low in numbers, these cells
have clonogenic and proliferative potential as shown micro-
scopically by their observed spread to the surrounding sub-
strate (Figure 4(C4,F4)). The data in Table 2 and Figure 5
agree with previous observations (briefly described in [30])
that the TID parameter is useful for planning treatments
involving these ‘slow’ hyperthermic thermal exposures.
However, the data in Figures 3 and 4 demonstrate that lon-
gitudinal studies are also important for effective characteriza-
tion of the cytotoxic effect of thermal dose, and that reliance
only on initial effects may not be indicative of longer-term
cell viability (compare survival for TIDs of 120 and 240 CEM43
on day 1 and day 14 in Figure 3). This choice of cell viability
assessment method and identification of relevant time points
is important due to the known timelines of different pro-
gramed mechanisms of cell death [23]. False negative find-
ings, where ‘dormant’ cells which have a transient loss of
their adherent and proliferative phenotype are overlooked
Figure 8. The dependence of RCEM on temperature. RCEM was calculated using
Equation (7) and the activation energy values obtained from the Arrhenius plot
and plotted as a function of temperature.
(A)
(B)
Figure 9. Comparison cell viability following ‘rapid’ ablative and ‘slow’ hyper-
thermic exposures using a temperature-dependent RCEM to calculate the TID.
The results of figure 6 were replotted using a TID calculated with
RCEM¼0.42 e0.0041  T (Equation (7). Cell viability is undetectable for both
heating strategies when TID >305þ 10 CEM43.
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either because they do not form colonies within the experi-
mental time frame, or because they are removed as part of a
floater cell population, must be avoided. Additionally, false
positive findings, where viability assessed on the day of
treatment (day 0) includes viable cells destined to die
through a programed form of cell death at a later time point,
should be excluded. In the case of this study, where the MTT
assay was used, the data in Figure 3 allowed informed selec-
tion of time points that best represent the fate and survival
of cells subjected to both high and low TIDs (all delivered as
‘slow’ hyperthermic exposures). For lower TID (120 and 240
CEM43), Figures 3 and 4 show detectable cell viability at later
time points (e.g., day 14), and the lower the TID, the higher
the number of unaffected cells and the earlier proliferation is
seen. For 120 CEM43, increased cell viability was evident
between days 1 and 2 for HT29 cells and between days 2
and 4 for HCT116 cells. For 240 CEM43, proliferation is seen
between days 7 and 14, for both cell lines. Hence assessing
cell viability for low TID exposures (	240 CEM43) at later
time points (i.e., >day 1, for HT29) would provide a mislead-
ing indication of viability due to the signal detected from
the survivors’ progeny. These cells will increase in number
over time. They have had no thermal exposure and their
existence will increasingly mask the extent of the therapeutic
effect on the initial cell population i.e., the response that will
be predicted by any dosimetry model. Thus the earliest time
point at which the assessment of the viability of cells treated
with 120 and 240 CEM43 could be undertaken in order to
minimize false positive and false negative contributions is
day 1.
Figure 3 shows that for higher TIDs (>240 CEM43), assess-
ing cell viability at earlier time points (e.g., day 1) would sig-
nificantly overestimate ultimate cell viability. For example,
cells subjected to 480 and 720 CEM43 when assessed on day
1 show 20% cell viability but undetectable levels from day
7 onwards (for both cell lines). Where cell viability became
undetectable after 10 days, it remained undetectable at later
time points (e.g., day 14). Thus Figure 3 shows that, for
higher TIDs, cell viability is adequately assessed using any
time point between day 7 and 14. In this study, day 10 was
chosen. These dose-dependent times of assessment response
obtained from ‘slow’ hyperthermic exposures were applied
to ‘rapid’ ablated exposures because the same cell death
mechanisms were expected to occur in both heating
regimes. This assumption was not contradicted by any of the
experimental findings in this study. For any cell line in vitro
with unknown thermal sensitivity, a longitudinal assessment
of cell survival, as undertaken in this study, can be per-
formed in order to identify the correct time points at which
to assess the response of cells to heat treatments. For clinical
applications in which such longitudinal assessment of the tis-
sue type under investigation may not be possible, quantifica-
tion of the thermal dose should be based on a ‘worst-case’
parameter value from the available literature in order to
stand the best chance of achieving the >99% cell kill typic-
ally required for cancer therapy.
In assessing the effect of a given TID on a cell population,
the ideal situation would be that all cells are subjected to a
uniform temperature, that is raised from, and returned to,
baseline instantaneously, for a precisely know length of time
(a ‘top hat’ distribution). This is not realizable in practice for
‘rapid’ ablative exposures which require higher temperature
and shorter duration. For these, it is important to minimize
the inhomogeneity in thermal dose, which is often due to
heat conduction throughout volumes either from external
sources (e.g., water baths) or convecting from internal sour-
ces (e.g., different temperature solutions being mixed).
Fundamentally, this requires the contribution to the TID from
the periods of temperature rise and fall to be minimized and
the contribution from constant temperature heating to be
maximized. In the present study, these challenges were
addressed by pre-heating a relatively large volume of the
medium into which a much smaller aliquot of cells in a
cooler suspension was added, with the aim of maximizing
the rate of rise to the target temperature. In addition, at the
end of heating, the bottom of the tube containing the cells
was immediately placed on dry ice. The relative success of
the chosen technique is demonstrated in Table 4. Whilst the
majority of thermal dose was delivered at a constant tem-
perature (58–76%, with a potential ‘outlier’ of 42%), signifi-
cant dose was still accumulated during heating (22–34%,
with potential ‘outliers’ of 14% and 43%), and with a small,
but not negligible, dose arising during cooling (6–22%, with
an outlier of 36%).
Where volumes of liquid are heated to high temperatures
for short periods of time, such as in this ‘rapid’ ablative heat-
ing study, temperature homogeneity is unlikely to be
achieved throughout the sample. For example, the smallest
TID difference that was measured between the bottom of
the sample (540 CEM43) and the top (1450 CEM43)
thermocouple during one of the ‘rapid’ ablative thermal
exposures (Table 3) demonstrates the difficulty in relating an
average TID to the thermal treatment outcome. The largest
difference (490–193 000 CEM43) further demonstrates the
potential scale for non-uniform dosing throughout the
medium volume. Furthermore, whilst the thermocouples
recorded temperature at fixed positions from which thermal
dose could be calculated, it is important to acknowledge
that the injected cell medium moves as illustrated in
Appendix A. As a result, cells will be subjected to a wide
range of TID which should lie between the minimum and
maximum measurements shown in Table 3. However, it is
impossible to know the temperature history of any individual
cell or the distribution of doses experienced by the cell
population. For these reasons an alternative approach to
quantifying dose is necessary. If the experimental procedures
detailed in this study are performed under carefully con-
trolled conditions, as described above, a temperature gradi-
ent with the lowest temperature in the bottom of the tube
and the highest temperature at the top is created, as would
be expected when cold liquid is introduced into the bottom
of a volume of warmer liquid. Measurement of the tempera-
ture at the bottom of the tube throughout exposure (as
shown in Figure 2) allows estimation of the lowest tempera-
ture, and therefore the minimum thermal dose (minTID) that
could be experienced by any cell in the treatment volume.
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The advantage of this approach is that it is reasonable to
assume that the cells exposed to the least dose would have
the greatest chance of surviving and therefore of being
detected in viability assays.
Using this approach, the cytotoxicity observed when a
minTID >340 CEM43 was achieved using ‘rapid’ ablative expo-
sures was lower than that seen using the same average TID
for ‘slow’ hyperthermic exposures, as shown in Figure 6. This
is an unexpected result because a significant number of cells
would have experienced significantly higher thermal doses
during ‘rapid’ ablative exposure, which according to Table 3
could be from 1940 to 193 000 CEM43. The viability of cells
treated with ‘rapid’ ablative thermal exposures became
undetectable for minTID between 540 and 620 CEM43 for
HT29 and 560 and 680 CEM43 for HCT116. For ‘slow’ hyper-
thermic exposures undetectable survival was achieved with
average thermal doses between 240 and 340 CEM43. This
result suggests that a TID target in clinical applications of
thermal ablation in cancer therapy of 650 CEM43 may offer
better efficacy for exposures delivered over a time shorter
than 10 s. The mathematical dependence of the TID parameter
on temperature suggests that only a small change in target
temperature is necessary to achieve this target for ‘rapid’ abla-
tive thermal exposures. For example, and assuming a top hat
temperature elevation, a 3 s exposure at 55.2 C would provide
235 CEM43. To achieve 650 CEM43, the target temperature
has to be elevated by only 1.5 C–56.7 C.
Arrhenius analysis and the damage index have also been
used to describe thermal insults to tissue [19]. The TID and
Arrhenius models share similar physical principles. The advan-
tage of the Arrhenius approach is that cell survival can be pre-
dicted directly, but in some cases, the mathematical
description of the equations underestimates the cell’s thermal
resilience at low temperatures [31]. In this study, it has been
shown that Arrhenius equations can be used to predict cell
survival after exposure of cells to ‘slow’ hyperthermic and
‘rapid’ ablative treatments in the range of 44–57 C with rea-
sonable accuracy associated with an error that does not
exceed 16% survival (Figure 7 and Table 5). The results for
both cell lines were combined in order to generalize the
results from this study within the bounds of the available cell
models. Thus the coefficient values (DE and A) obtained from
Figure 7(A) are applicable to the description of the survival of
both cell lines. In addition, the Arrhenius activation energy DE,
as extracted from the measurement of the experimental cell
survival (and hence injury rates) can be used to calculate a
temperature-dependent RCEM (Figure 8) that offers a more
accurate prediction of cell survival at high magnitude thermal
insults, irrespective of the heating strategy employed (Figure 9)
and shows that viability is undetectable if cells are exposed to
a TID of 305±10 CEM43, irrespective of the heating strategy.
The results presented in this study show that, for the two
cell lines studied RCEM increases with temperature according
to Equation (7). At high temperatures, such as those encoun-
tered in ‘rapid’ ablative treatments, even a small change in R
will have a significant effect on the calculation of TID. For
example, using the widely accepted value of RCEM¼0.5,
Equation (1), with a temperature of 57 C held for 2 s,
(assuming a top hat temperature distribution) gives an esti-
mated minTID of 550 CEM43 (close to the highest minTID at
which viability above 3% was detected for either cell line as
shown in Figure 6), adjusting RCEM by 0.03 (calculated using
Equation (7) and shown in Figure 8) equates to an R-corrected
minTID of 240 CEM43 (Figure 9). This is lower than the average
TID of 350 CEM43 (Figure 6) (or TID of 305 CEM43 if a tempera-
ture-dependent RCEM of 0.51 (Equation (7) is used instead
(Figure 9)) that produces undetectable cell viability (Table 2)
during ‘slow’ hyperthermic exposures. It is also lower than the
minTID of 630 CEM43 (Figure 6) (or TID of 300 CEM43 if a tem-
perature-dependent RCEM of 0.53 (Equation (7) is used instead
(Figure 9)) that produces complete cell kill (Table 3) during
‘rapid’ ablative exposures. Thus the difference in survival of
cells during the ‘rapid’ exposure may not be an unexpected
result and using a temperature-dependent RCEM, as shown
here, can improve the normalization of different thermal his-
tories using the TID model. Although Equations 6 and 7
extend the original TID model to provide a continuously vary-
ing temperature-dependent RCEM, instead of 2 temperature-
stepped values (0.25 and 0.5), they remain simple equations
that attempt to describe very complex physical and biological
functions [32–35] which collectively underlie the response of
cells to thermal insults and ultimately determine whether they
live or die. These considerations underline the usefulness of a
simplified TID model with well-characterized parameters (such
as a temperature-dependent RCEM) for prediction.
In comparing the use of the TID and Arrhenius analysis in
predicting the biological effects of thermal treatments, there
needs to be a note of caution, since different injury models
may have different sensitivities to the thermal insult, making
extrapolation of TID values inaccurate. Additional mechanisms
may be in play which may result in non-linear responses, such
as the dependence of cell killing on the rate of temperature
rise. For example, elegant experiments undertaken by
Dewhirst and colleagues have shown that for the same ther-
mal dose, and using heating rates between 0.1 and 1 C/min,
rapid heating is more effective at causing vascular stasis than
slower heating [36]. In in-vitro experiments, Herman et al. [37]
have shown that if temperatures in the hyperthermia range
up to 42.4 C are used then slow heating rates are associated
with increased survival of Chinese hamster ovary cells. More
recently, Goldberg and colleagues showed that the Arrhenius
damage integral may be dependent on the rate of heat trans-
fer [5]. Our study used relatively high heating rates for both
‘slow’ hyperthermic (3 Cs1) and ‘rapid’ ablative exposures
(10 Cs1), and as such we cannot draw firm conclusions
about the effect of heating rate on cell survival.
In summary, the data in this paper contribute to an
improved understanding of the applicability of the TID and
Arrhenius models to cancer cells heated in vitro and have a
potential impact on attempts to standardize a dosimetric
parameter for ‘rapid’ ablative heating. It has been demon-
strated that:

 Cells can withstand an average TID of 240 CEM43, deliv-
ered using a ‘slow’ hyperthermic (15min, 47 C)
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treatment, remaining in a loosely-adherent state for sev-
eral days, while retaining their proliferative potential.

 Spatially-averaged TID provides a reasonable predictor of
cell viability for thermal exposures given using ‘slow’
hyperthermic treatments.

 Although the range of delivered ‘rapid’ ablative doses
within each sample volume can differ by several orders of
magnitude, the minimum dose (minTID) has proved to be
a useful concept to link with cell survival.

 The standard TID equation is not adequate to normalize
the biological effect of cells subjected to ablative thermal
exposures >340 CEM43 unless a temperature-dependent
RCEM as described here is used.

 Using a temperature-dependent RCEM, undetectable cell
viability is observed when cells are treated with a TID
above 305±10 CEM43, irrespective of the heating strategy.
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